SavedAdd your journal

Journals / Gülhane Tıp Dergisi / 2009 / Cilt: 51 - Sayı: 4

The role of 18F-fluoro-2-deoxyglucose positron emission tomography imaging in thyroid cancers

Tiroid kanserlerinde flor-18 florodeoksiglukoz pozitron emisyon tomografi görüntülemenin yeri

M. Özdeş EMER
Seyfettin ILGAN
ENGİN ALAGÖZ
Nuri ARSLAN
A. Özgür KARAÇALIOĞLU
Bengül GÜNALP
M. Ali ÖZGÜVEN
Pages
229–234
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These results show that FDG PET is a valuable test in the follow-up of patients with differentiated thyroid cancers.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:There has recently been an increasing number of studies demonstrating the sensitivity of 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG PET) in the management of differentiated and de-differentiated thyroid cancers.
📊
Key Findings & Data:With this aim 36 patients (18 male, 18 female) with differentiated thyroid cancer who had either non-physiologic I-131 uptake outside the thyroid gland in whole body scanning, high Tg levels with negative whole body I-131 scanning, Tg antibody positivity, classified in high risk group or suspicious lesions with other imaging modalities were performed FDG PET imaging.
💡
Conclusion & Impact:These results show that FDG PET is a valuable test in the follow-up of patients with differentiated thyroid cancers.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

There has recently been an increasing number of studies demonstrating the sensitivity of 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG PET) in the management of differentiated and de-differentiated thyroid cancers. This prospective study was planned to investigate the value of FDG PET in the follow-up of patients with thyroid cancers. With this aim 36 patients (18 male, 18 female) with differentiated thyroid cancer who had either non-physiologic I-131 uptake outside the thyroid gland in whole body scanning, high Tg levels with negative whole body I-131 scanning, Tg antibody positivity, classified in high risk group or suspicious lesions with other imaging modalities were performed FDG PET imaging. Sensitivity, specificity, positive predictive value and negative predictive value in whole of the group were 54.5%, 92.8%, 92.3% and 56.5%, respectively. Sensitivity and specificity of FDG PET in the group with TSH levels of <2 &#956;IU/ml were 66.6% and 100%, respectively, whereas these values were 40% and 87.5%, respectively in the group with TSH levels of >30 &#956;IU/ml. These results show that FDG PET is a valuable test in the follow-up of patients with differentiated thyroid cancers.

Özet

Son yıllarda 2-[18F]-fluoro-2-deoxy-d-glucose (F-18 FDG) pozitron emisyon tomografinin (PET) diferansiye ve de-diferansiye tiroid kanserlerinde de duyarlı bir yöntem olduğuna ilişkin çalışmaların sayısı artmıştır. Bu prospektif çalışma tiroid kanserli olguların takibinde F-18 FDG PET'in değerinin araştırılması amacıyla planlanmıştır. Bu amaçla I-131 tüm vücut taramasında tiroid yatağı dışında fizyolojik olmayan tutulum tespit edilen, Tg düzeyi yüksek ve I-131 tüm vücut taraması negatif olan, anti-Tg antikor düzeyleri yüksek olan, yüksek risk grubunda değerlendirilen veya diğer görüntüleme yöntemlerinde şüpheli bulgu tespit edilen 36 diferansiye tiroid kanserli olguya (18 erkek, 18 kadın) FDG PET görüntüleme uygulandı. Tüm grupta FDG PET'in duyarlılığı %54.5, özgüllüğü %92.8, pozitif öngörü değeri %92.3 ve negatif öngörü değeri %56.5 olarak hesaplanmıştır. TSH seviyesi 30 μIU/ml olan grupta duyarlılık %40, özgüllük %87.5 olarak bulunmuştur. Bu bulgular FDG PET'in diferansiye tiroid kanserli olguların takibinde değerli bir test olduğunu göstermektedir.

🔖

Cite This Article

EMER, M. Ö., ILGAN, S., ALAGÖZ, E., ARSLAN, N., KARAÇALIOĞLU, A. Ö., GÜNALP, B., ÖZGÜVEN, M. A. (2009). The role of 18F-fluoro-2-deoxyglucose positron emission tomography imaging in thyroid cancers. Gülhane Tıp Dergisi, Cilt: 51 - Sayı: 4, 229–234. https://ajindex.com/articles/226150

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18-fluorodeoxyglucose. J Nucl Med 1987; 28: 910-914
  2. Sisson JK, Ackermann RJ, Meyer MA. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrin Metabol 1993; 77: 1090-1094
  3. Feine U. Fluor-18-deoxyglucose positron emission tomography in differentiated thyroid cancer. Eur J Endocrinol 1998; 138: 492-496
  4. Grünwald F, Kalicke T, Feine U, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999; 26: 1547-1552
  5. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl 1997; 24: 1342-1348
  6. Hosaka Y, Tawata M, Kurihara A, Ohtaka M, Endo T, Onaya T. The regulation of two distinct glucose transporter (GLUT1 and GLUT4) gene expressions in cultured rat thyroid cells by thyrotropin. Endocrinology 1992; 131: 159-165
  7. Feine U, Lietzenmayer R, Hanke JP, Held J, Wöhrle H, Müller-Schauenburg W. Fluorine-18-FDG and iodine- 131-iodide uptake in thyroid cancer. J Nucl Med 1996; 37: 1468-1472
  8. Wang W, Macapinlac H, Finn R, et al. PET scanning with 18F- fluoro-2-deoxyglucose can localize residual differentiated thyroid cancer in patients with negative I-131 whole body scans. J Clin Endocrinol Metab 1999; 84: 2291-2302
  9. Schlüter B, Bohuslavizki KH, Beyer W, et al. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131-I scan. J Nucl Med 2001; 42: 71-76.